152 related articles for article (PubMed ID: 23837479)
1. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
Serdjebi C; Seitz JF; Ciccolini J; Duluc M; Norguet E; Fina F; Lacarelle B; Ouafik L; Dahan L
Pharmacogenomics; 2013 Jul; 14(9):1047-51. PubMed ID: 23837479
[TBL] [Abstract][Full Text] [Related]
2. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
3. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
[TBL] [Abstract][Full Text] [Related]
4. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Vivaldi C; Crucitta S; Catanese S; Cucchiara F; Arrigoni E; Pecora I; Rofi E; Fornaro L; Salani F; Massa V; Vasile E; Morganti R; Danesi R; Del Re M
Pharmacogenomics J; 2021 Apr; 21(2):233-242. PubMed ID: 33462346
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
7. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
[TBL] [Abstract][Full Text] [Related]
8. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Yonemori K; Ueno H; Okusaka T; Yamamoto N; Ikeda M; Saijo N; Yoshida T; Ishii H; Furuse J; Sugiyama E; Kim SR; Kikura-Hanajiri R; Hasegawa R; Saito Y; Ozawa S; Kaniwa N; Sawada J
Clin Cancer Res; 2005 Apr; 11(7):2620-4. PubMed ID: 15814642
[TBL] [Abstract][Full Text] [Related]
9. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples.
Giovannetti E; Laan AC; Vasile E; Tibaldi C; Nannizzi S; Ricciardi S; Falcone A; Danesi R; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):720-5. PubMed ID: 18600531
[TBL] [Abstract][Full Text] [Related]
10. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
[TBL] [Abstract][Full Text] [Related]
11. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Innocenti F; Jiang C; Sibley AB; Denning S; Etheridge AS; Watson D; Niedzwiecki D; Hatch AJ; Hurwitz HI; Nixon AB; Furukawa Y; Kubo M; Crona DJ; Kindler HL; McLeod HL; Ratain MJ; Owzar K
Pharmacogenet Genomics; 2019 Aug; 29(6):123-131. PubMed ID: 30889042
[TBL] [Abstract][Full Text] [Related]
12. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.
Tibaldi C; Giovannetti E; Tiseo M; Leon LG; D'Incecco A; Loosekoot N; Bartolotti M; Honeywell R; Cappuzzo F; Ardizzoni A; Peters GJ
Ann Oncol; 2012 Mar; 23(3):670-677. PubMed ID: 21652582
[TBL] [Abstract][Full Text] [Related]
13. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
[TBL] [Abstract][Full Text] [Related]
14. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
Ueno H; Kaniwa N; Okusaka T; Ikeda M; Morizane C; Kondo S; Sugiyama E; Kim SR; Hasegawa R; Saito Y; Yoshida T; Saijo N; Sawada J
Br J Cancer; 2009 Mar; 100(6):870-3. PubMed ID: 19293806
[TBL] [Abstract][Full Text] [Related]
15. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.
Mercier C; Raynal C; Dahan L; Ortiz A; Evrard A; Dupuis C; Blesius A; Duluc M; Franceschini F; Giacometti S; Salas S; Milano G; Favre R; Seitz JF; Ciccolini J
Pharmacogenet Genomics; 2007 Oct; 17(10):841-4. PubMed ID: 17885621
[TBL] [Abstract][Full Text] [Related]
16. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Joerger M; Burgers JA; Baas P; Doodeman VD; Smits PH; Jansen RS; Vainchtein LD; Rosing H; Huitema AD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2012 Jan; 69(1):25-33. PubMed ID: 21590444
[TBL] [Abstract][Full Text] [Related]
17. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X; Chen W; Fan H; Zhu B
Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
[TBL] [Abstract][Full Text] [Related]
18. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
Ciccolini J; Dahan L; André N; Evrard A; Duluc M; Blesius A; Yang C; Giacometti S; Brunet C; Raynal C; Ortiz A; Frances N; Iliadis A; Duffaud F; Seitz JF; Mercier C
J Clin Oncol; 2010 Jan; 28(1):160-5. PubMed ID: 19933910
[TBL] [Abstract][Full Text] [Related]
19. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
[TBL] [Abstract][Full Text] [Related]
20. The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
Li H; Wang X; Wang X
Int J Biol Markers; 2014; 29(3):e224-32. PubMed ID: 24557790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
